Taro Pharmaceutical Industries Stock Fundamentals
Taro Pharmaceutical Industries fundamentals help investors to digest information that contributes to Taro Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Taro Stock. The fundamental analysis module provides a way to measure Taro Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Taro Pharmaceutical stock.
Taro |
Taro Pharmaceutical Industries Company Return On Equity Analysis
Taro Pharmaceutical's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Taro Pharmaceutical Return On Equity | 0.0306 |
Most of Taro Pharmaceutical's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Taro Pharmaceutical Industries is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Taro Pharmaceutical Industries has a Return On Equity of 0.0306. This is 100.13% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on equity for all United States stocks is 109.87% lower than that of the firm.
Taro Pharmaceutical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Taro Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Taro Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Taro Pharmaceutical competition to find correlations between indicators driving Taro Pharmaceutical's intrinsic value. More Info.Taro Pharmaceutical Industries is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about 0.07 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Taro Pharmaceutical Industries is roughly 14.57 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Taro Pharmaceutical's earnings, one of the primary drivers of an investment's value.Taro Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Taro Pharmaceutical's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Taro Pharmaceutical could also be used in its relative valuation, which is a method of valuing Taro Pharmaceutical by comparing valuation metrics of similar companies.Taro Pharmaceutical is currently under evaluation in return on equity category among its peers.
Taro Fundamentals
| Return On Equity | 0.0306 | |||
| Return On Asset | 0.0021 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 735.67 M | |||
| Shares Outstanding | 37.58 M | |||
| Shares Owned By Insiders | 78.48 % | |||
| Shares Owned By Institutions | 13.06 % | |||
| Number Of Shares Shorted | 73.56 K | |||
| Price To Earning | 14.57 X | |||
| Price To Book | 0.89 X | |||
| Price To Sales | 2.59 X | |||
| Revenue | 629.18 M | |||
| Gross Profit | 293.13 M | |||
| EBITDA | 52.6 M | |||
| Net Income | 53.87 M | |||
| Cash And Equivalents | 806.25 M | |||
| Cash Per Share | 21.45 X | |||
| Total Debt | 369.06 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 3.60 X | |||
| Book Value Per Share | 47.70 X | |||
| Cash Flow From Operations | 132.39 M | |||
| Short Ratio | 3.20 X | |||
| Earnings Per Share | 1.43 X | |||
| Target Price | 43.0 | |||
| Number Of Employees | 24 | |||
| Beta | 0.56 | |||
| Market Capitalization | 1.62 B | |||
| Total Asset | 2.16 B | |||
| Retained Earnings | 2.41 B | |||
| Working Capital | 950.88 M | |||
| Current Asset | 1.88 B | |||
| Current Liabilities | 245.46 M | |||
| Net Asset | 2.16 B |
Pair Trading with Taro Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Taro Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Taro Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Union Pacific could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Union Pacific when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Union Pacific - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Union Pacific to buy it.
The correlation of Union Pacific is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Union Pacific moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Union Pacific moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Union Pacific can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Taro Stock
If you are still planning to invest in Taro Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taro Pharmaceutical's history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |